Lifeward (NASDAQ:LFWD) Stock Rating Lowered by Zacks Research

Lifeward (NASDAQ:LFWD) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other research analysts have also recently commented on LFWD. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lifeward in a report on Tuesday, April 21st. HC Wainwright raised their target price on shares of Lifeward to $10.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $10.00.

Lifeward Stock Down 1.5%

Shares of LFWD opened at $7.17 on Wednesday. Lifeward has a 12 month low of $4.14 and a 12 month high of $15.00. The firm’s 50 day moving average is $6.92 and its 200-day moving average is $7.08. The stock has a market capitalization of $20.18 million, a PE ratio of -0.36 and a beta of 0.36. The company has a current ratio of 2.40, a quick ratio of 1.82 and a debt-to-equity ratio of 1.16.

Lifeward (NASDAQ:LFWD) last announced its earnings results on Friday, May 15th. The company reported ($6.70) EPS for the quarter, missing the consensus estimate of ($1.18) by ($5.52). Lifeward had a negative return on equity of 243.14% and a negative net margin of 123.66%.The business had revenue of $3.92 million for the quarter, compared to the consensus estimate of $5.78 million. Equities research analysts forecast that Lifeward will post -4.27 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in LFWD. Citadel Advisors LLC increased its stake in Lifeward by 1,271.8% in the third quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock valued at $152,000 after acquiring an additional 198,406 shares during the last quarter. Virtu Financial LLC increased its stake in Lifeward by 158.0% in the fourth quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock valued at $35,000 after acquiring an additional 37,037 shares during the last quarter. Jane Street Group LLC increased its stake in Lifeward by 77.3% in the fourth quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock valued at $40,000 after acquiring an additional 29,927 shares during the last quarter. Finally, HRT Financial LP increased its stake in Lifeward by 149.7% in the fourth quarter. HRT Financial LP now owns 49,081 shares of the company’s stock valued at $28,000 after acquiring an additional 29,423 shares during the last quarter. 26.76% of the stock is owned by institutional investors.

More Lifeward News

Here are the key news stories impacting Lifeward this week:

• Negative Sentiment: HC Wainwright cut Lifeward’s 2026 earnings outlook sharply, now expecting a much larger loss per share for FY2026 than previously forecast. Lifeward analyst estimates
• Negative Sentiment: The firm also reduced Q2 2026, Q3 2026, and Q4 2026 EPS estimates, suggesting weaker profitability in the near term. Lifeward analyst estimates
• Negative Sentiment: HC Wainwright lowered longer-term EPS projections for FY2027, FY2028, and FY2029 as well, indicating a slower path to earnings recovery. Lifeward analyst estimates
• Neutral Sentiment: Despite the lower estimates, HC Wainwright kept a Buy rating and a $10 price target on Lifeward, implying the firm still sees upside from current levels. Lifeward analyst estimates
• Positive Sentiment: HC Wainwright raised its FY2030 EPS estimate, suggesting the company could eventually return to stronger profitability over the long term. Lifeward analyst estimates

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.